Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women
Dolutegravir (DTG), an integrase strand transfer inhibitor, is metabolized by UGT1A1 and CYP3A4. It has not been studied in pregnant women or infants. This study described DTG exposure during pregnancy compared to postpartum and in infant washout samples after delivery. IMPAACT protocol P1026s is an ongoing, nonrandomized, open-label, parallel-group, multi-center phase-IV prospective study of antiretroviral…